Pharmafile Logo

GRI

- PMLiVE

Novo Nordisk’s Ozempic is quick out of the blocks, chasing Lilly’s Trulicity

Firm relying on launch success in pressured US market

- PMLiVE

J&J’s Invokana aces diabetic kidney disease trial, setting up filings

It could be the first new drug in 15 years to slow kidney damage development

Research Partnership launches new patient Living with Diabetes (LATAM) 2018 report

Living with Diabetes is a study conducted amongst approximately 200 Type 2 (T2D) diabetes patients in Brazil and Mexico. The report will consist of quantitative 30-minute online and qualitative telephone...

Research Partnership

- PMLiVE

Mylan sees the UK paving the way for an insulin game changer

As biosimilars surge into the insulin market, governments  are urged to seize ‘the opportunity of the century’

- PMLiVE

Novo’s diabetes pill defeats Merck’s Januvia in trial

Oral semaglutide also outshines its best-selling diabetes injectable Victoza

Lars Rebien Sørensen becomes chairman of Novo Holdings

He will take up the new role 1 July

- PMLiVE

FDA starts review of Sanofi’s oral type 1 diabetes drug

The US regulator has started its review of Sanofi and Lexicon Pharma’s sotagliflozin for type 1 diabetes, which the firms say could have blockbuster potential.Sotagliflozin – which has the proposed...

- PMLiVE

Novo Nordisk expands cell therapy R&D, says type 1 diabetes cure a step closer

Company has reached milestone in stem cell therapy as it looks to broaden range beyond diabetes

- PMLiVE

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Insulin specialist bounces back with encouraging signs from Ozempic launch

- PMLiVE

Novo Nordisk appoints new general manager

Pinder Sahota also becomes the corporate vice president, UK

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links